Compare Hormel Foods Corp (HRL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Hormel Foods Corp trades at $19.2 (market cap $10.69B), while State Street SPDR S&P Biotech ETF trades at $154 (market cap $10.11B). The key difference: Hormel Foods Corp and State Street SPDR S&P Biotech ETF are close in size by market cap, and Hormel Foods Corp pays a 6.02% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HRL | XBI | |
|---|---|---|
Market Cap | $10.69B | $10.11B |
Volume | 10,041,387 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $26.50 | $169.55 |
52-Week Low | $19.42 | $104.99 |
Typical Hold Time | 99 Days | 38 Days |
Enterprise Value | $12.67B | — |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.23, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company maintains a P/E of 31.32 and P/S of 0.88, with net income margin at 2.82%. Recent $1.06B Brakebush acquisition aims to expand foodservice presence, while dividend consistency remains a key investor focus with 60 consecutive years of increases.
Outlook remains cautious with mixed analyst sentiment (20% buy, 57% hold) and a $24.25 consensus target offering 26% upside. Risks include margin pressure, acquisition integration challenges, and declining dividend growth rates. The stock presents value potential but requires monitoring of operational execution amid competitive pressures.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
